ImmunoGen (NASDAQ:IMGN) Director Daniel M. Junius sold 25,000 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $12.02, for a total transaction of $300,500.00. Following the transaction, the director now owns 209,987 shares of the company’s stock, valued at $2,524,043.74. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of IMGN stock opened at $9.99 on Friday. The company has a debt-to-equity ratio of -0.11, a quick ratio of 4.94 and a current ratio of 4.95. ImmunoGen has a 52 week low of $2.84 and a 52 week high of $13.41.
ImmunoGen (NASDAQ:IMGN) last announced its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million for the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the prior year, the business earned ($0.39) EPS. The business’s revenue for the quarter was up 185.5% on a year-over-year basis. equities research analysts forecast that ImmunoGen will post -1.09 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its stake in shares of ImmunoGen by 33.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 441,445 shares of the biotechnology company’s stock valued at $3,378,000 after buying an additional 109,547 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of ImmunoGen in the fourth quarter valued at $3,205,000. Virtus Fund Advisers LLC bought a new position in shares of ImmunoGen in the fourth quarter valued at $346,000. Swiss National Bank grew its stake in shares of ImmunoGen by 16.6% in the fourth quarter. Swiss National Bank now owns 161,200 shares of the biotechnology company’s stock valued at $1,033,000 after buying an additional 23,000 shares in the last quarter. Finally, TD Asset Management Inc. bought a new position in shares of ImmunoGen in the third quarter valued at $286,000. Institutional investors own 78.25% of the company’s stock.
A number of equities analysts have recently issued reports on IMGN shares. Zacks Investment Research upgraded shares of ImmunoGen from a “sell” rating to a “hold” rating in a research note on Monday, March 19th. Leerink Swann reiterated an “outperform” rating on shares of ImmunoGen in a research report on Monday, March 26th. BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. Cantor Fitzgerald set a $5.00 price objective on shares of ImmunoGen and gave the stock a “hold” rating in a report on Sunday, March 25th. Finally, ValuEngine lowered shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Wednesday, March 28th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $10.79.
ILLEGAL ACTIVITY WARNING: “ImmunoGen (IMGN) Director Sells $300,500.00 in Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/daniel-m-junius-sells-25000-shares-of-immunogen-inc-imgn-stock.html.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.